
THC drinks are flying off shelves. Can it last?
'Immediately, the sales took off,' said Halper. 'We've never seen anything explosive like this.'
After just two years, THC beverages make up about 15% of overall sales, he said. 'It's hard to believe this growth isn't going to be astronomical.'
The time is right for a THC beverage boom. Many Americans are embracing a California sober lifestyle — drinking less alcohol, which they see as harmful to health, and trying out marijuana instead. A study published in 2024 found that a higher number of Americans reported using cannabis every day than drinking alcohol daily.
And thanks to what many consider to be a loophole in the 2018 farm bill, THC beverage makers have been able to rapidly launch their products across the country with little oversight. Now, states are trying to make sense of the bill's language, setting up their own regulations and raising questions for the future of the fast-growing industry.
For years, beverage companies toyed with the idea of using THC in drinks. But cannabis is a tricky business. Marijuana is a 'schedule I controlled substance' in the United States, meaning companies that sell marijuana products legally don't get certain tax benefits. The classification also makes it hard for those firms to get funding from financial institutions wary of breaking federal laws.
So drink makers avoided cannabis. Then the 2018 farm bill changed the game.
The lengthy document governs a wide range of agricultural and food assistance programs, and it includes a few pages that legalized the production of hemp, defined as a cannabis plant that has no more than 0.3% delta-9 THC on a dry-weight basis (cannabis plants with higher concentrations of THC are classified as marijuana). That language spawned a fast-growing market of technically legal THC beverages that are still potent enough to make you feel something.
At the time, 'these drinks did not exist,' said Frank Colombo, managing director of Viridian Capital Advisors, which specializes in cannabis. 'Nobody anticipated this whole category of hemp-based intoxicants, let alone hemp-based THC drinks.'
In 2020, the US market for hemp-derived THC drinks amounted to about $400,000, according to Brightfield Group, a consumer insights and market research firm that has been tracking the THC drink industry. By 2024, the market had grown nearly 10 times bigger, reaching $382 million dollars. This year, it will grow to $571 million, Brightfield predicts, with more expansion to come.
THC beverage makers have been exempt from the onerous regulations that apply to marijuana companies. But some entrepreneurs seek a Goldilocks zone for regulation: Too little could allow bad actors — those who market to children or sell high-dosage products made with synthetic ingredients — to proliferate, encouraging bans. Too much would constrain growth. But the right amount would legitimize their businesses, putting them on a path to skyrocketing growth.
Companies are betting that things will go their way. Experts are not so sure.
'I do not think it's going to go perfectly,' said Hilary Bricken, an attorney with Husch Blackwell who focuses on the hemp and cannabis industries. She can 'appreciate the confidence' of young companies trying to forge a path, but 'it's still going to be a bumpy road.'
When Cann first launched in 2019, the THC beverage was only available at a handful of cannabis dispensaries.
'At the time, we thought that was the only place you could sell these products,' explained Jake Bullock, co-founder and CEO of Cann. The drink had initially derived its THC and CBD, a non-psychoactive cannabinoid present in Cann drinks, from marijuana. Then in 2022, a new Minnesota law helped clarify the farm bill's language, explicitly allowing certain hemp-derived THC products to be sold to customers aged 21 or older.
'We were like, 'Well, wait, can we extract THC and CBD from hemp?'' Bullock recounted.
They could, and it took just 60 days. Cann launched the updated product in Minnesota in October of that year.
Today, Cann is sold in stores across 30 states and available direct-to-customer in at least 35 states. In 2024, revenue grew over 70%, according to the company. It expects over 100% growth this year.
Cann and other THC drink brands describe their products as social tonics, designed to give a light, mellow buzz that, they say, will help you feel good at parties but not hungover the next day. Cann's drinks come in flavors like blood orange cardamom and yuzu elderflower and have no more than 10 milligrams of THC per can.
'If you think about alcohol and caffeine, we drink these in microdoses,' Bullock said. 'There's a reason you can have a few cups of coffee or a couple of glasses of wine. We wanted to capture that same kind of concept.'
Even shoppers who aren't familiar with THC drinks are in the market for a new kind of beverage: Stroll down a refrigerator aisle and you'll see prebiotic sodas in countless flavors, botanical teas, canned lattes with a variety of milks, sparkling everythings, non-alcoholic beers and more.
And over the past few years, Cann has been joined by scores of competitors.
For example, hi Seltzer, a calorie-free drink that comes in fruit flavors and contains five milligrams of THC, launched in 2023. 'We're running somewhere between 1.2 (million) and 1.5 million cans a month,' CEO Louis Police said in April, 'which doesn't even satisfy the demand.'
BRĒZ, a THC beverage brand that use lion's mane mushroom extract, has seen sales explode since it started in 2023. In 2024, the company recorded about $28 million in revenue, said founder and CEO Aaron Nosbisch. This year, it's on track to hit about $75 million.
The market has also attracted alcohol makers like Samantha Lee, co-founder of Hopewell Brewing Company in Chicago, Illinois. Last year, she and her Hopewell co-founders (plus one more) launched Choom, a sparkling canned THC beverage that comes in mostly citrus flavors.
'We're seeing a lot of our current customer base who are really excited about (Choom),' she said.
Lee is optimistic that Illinois will regulate the market in a way that well help business thrive.
'We're seeing a lot of positive movements in Illinois that will codify this as a law,' she said. But until that happens, major retailers may avoid selling brands like Choom. Without clear regulation, 'there's only so much we can do.'
The Hemp Beverage Alliance (HBA), a trade group formed two years ago, shares its own regulatory principles on labeling, dosing, age restrictions and more on its website. Brands are also educating distributors, retailers and consumers about their THC drinks. But self-regulation can only go so far.
'It's going to be challenging for someone to truly break out… until there is something at the federal level that is a clear indication that these products can be scaled and will be legal,' said Duane Stanford, executive editor and publisher of Beverage Digest, a trade publication.
Ideally, there would be 'a federal framework that guides the entire country' said Christopher Lackner, president of the HBA.
But that's a moonshot, at least in the near term. For now, the alliance, which represents over 250 brands, retailers and distributors across North America, is working toward getting industry-friendly regulation at the state level.
Half of US states permit hemp-derived delta-9 THC beverages as of May 1, according to the HBA. The rest either severely limit THC content in these drinks, prohibit their sale outright or have not regulated the product, by the HBA's count.
As states decide how to move forward, the federal government could crack down or make hemp illegal again.
'If the FDA starts getting increased accounts of, let's say, kids getting ahold of this stuff, or consumers being misled (or) having adverse reactions,' it might set its own restrictions, said Bricken, the Husch Blackwell attorney.
Then there's the question of the farm bill.
The current legislation has been extended through later this year. But if the administration decides to make hemp illegal in the next farm bill, it would have a chilling effect on the THC beverage industry, said Whitt Steineker, partner at Bradley and co-chair of the law firm's cannabis industry team.
'You would see the money flow really dry up,' he said.
Halper, of Top Ten Liquors, isn't quite sure what to expect from the federal government.
'We all talk about the next farm bill,' he said, adding: 'None of us control what is happening in Washington.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
Leach International Corporation Approves FDH Electronics Brand Stealth Aerospace as an Authorized Channel Partner for the Commercial Airline and MRO Markets
Commercial aviation industry to benefit from access to Leach's trusted product lines through a reliable, scaled and independent distribution partner FDH Electronics & Leach Aerospace OKLAHOMA CITY, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Oklahoma-based FDH Electronics, a unified FDH Aero division focused solely on serving the mil-aero market's electronic component needs, is pleased to announce that its aftermarket division, Stealth Aerospace, has been named as an approved distribution channel by Leach International Corporation to support commercial airline and MRO customers. This strategic partnership builds on the companies' long-standing relationship and reinforces their shared commitment to deliver best-in-class service, product availability and technical support to the commercial aviation aftermarket sector. Alon Glickstein, Vice President at FDH Electronics, commented: 'We are incredibly proud to have established this partnership with Leach International. Their long-standing reputation for high-reliability products fits perfectly with our mission at FDH Electronics — to provide our customers with exceptional service, technical support, and inventory availability that meets their evolving needs.' Leach International, a leading manufacturer of advanced electrical switches, relays, and power distribution components for the aerospace and defense markets, sees this partnership as a key step toward strengthening its presence in the aftermarket segment. Justin Coates, Vice President of Sales & Marketing at Leach International Corporation, added: 'This agreement with FDH Electronics' Stealth Aerospace division ensures that Leach's products will be supported with an incredibly high level of service. Their proven performance in the aerospace aftermarket gives us full confidence that customers will benefit from rapid access to inventory, technical insight, and dedicated aftermarket expertise.' This announcement marks a new chapter in aftermarket excellence and provides the commercial aviation industry with access to Leach's trusted product lines through a specialized and reliable distribution partner. About FDH ElectronicsFDH Electronics is a global one-stop shop with one of the most expansive inventory levels in the industry, built on FDH Aero's industry-leading supply chain solutions. It supplies a variety of interconnect, wire and cable, and electromechanical components for the aerospace, defense, and space markets. FDH Electronics is your go-to resource for value-added connectors, 1553 Data Bus interconnect products, custom harnesses, high-performance aerospace-grade wire and cable, and high-frequency RF connectors. When you need critical interconnect or electromechanical components, you can rely on FDH Electronics to deliver. To search by part number, please visit: Contact:Heather RosenowExecutive Vice President, Marketing & Communicationsmediarelations@ About Leach International CorporationLeach International Corporation has been a leader in aerospace switching and control technology since 1919. Leach designs and manufactures high-reliability relays, contactors, and power distribution systems for aerospace, defense, and industrial applications. Contact:relayed@ A photo accompanying this announcement is available at in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Snap Stock Plunged After Earnings. Buy the Dip?
Key Points Sponsored Snaps are showing strong engagement and conversion gains. Subscription revenue from Snapchat+ is growing quickly from a small base. Heavy stock-based compensation and dilution keep valuation concerns high. 10 stocks we like better than Snap › Snap (NYSE: SNAP), the parent company of social media platform Snapchat, took a hard hit following its second‑quarter earnings release earlier this month. Shares tumbled, driven by worries about slowing growth, execution missteps, and a worsening net loss. But dig deeper, and the underlying narrative is more nuanced; there were a lot of positives in the report, too. Revenue and users continue to grow at a robust rate, free cash flow has turned positive year over year, and new ad formats, such as sponsored Snaps, are demonstrating real engagement traction. Given the mix of good and bad in its underlying business and the stock's recent sell-off, it makes sense to check whether the shares have been pushed into oversold territory. Let's look at what changed in the business and what it might mean for investors today. Momentum in key areas Snap reported second-quarter revenue of $1.345 billion, marking a 9% gain from a year earlier. Further, the lifeblood of the company -- user activity -- performed exceptionally well. Daily active users (DAUs) rose 9% to 469 million, while monthly active users (MAUs) climbed 7% to 932 million. Operating cash flow reached $88 million, and free cash flow came in positive at $24 million, a notable reversal from the previous year, when the company burned cash. Still, Snap posted a net loss of $263 million (wider than a net loss of $249 million in the year-ago quarter), and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) slid lower on a year-over-year basis to $41 million, underscoring that profitability remains out of reach. An ad platform glitch -- where auction settings pushed some campaigns to clear at unusually low prices -- weighed on performance early in the quarter. Snap reversed the change mid-period, and management said that advertiser activity is of my favorite data points to support the bull case: On the diversification front, "other revenue" -- primarily from subscriptions like Snapchat+ -- grew 64% year over year, and Snapchat+ subscribers rose roughly 42%, nearing 16 million. One of the quarter's most promising developments was sponsored Snaps -- video ads delivered directly into users' inboxes. Snap co-founder Evan Spiegel said in the company's second-quarter earnings call that after a user opens a sponsored Snap from their chat feed, they "exhibit significantly higher engagement per full-screen ad view, driving a 2x increase in conversion, a 5x increase in click-to-convert ratios and a 2x increase in website dwell times compared to other inventories. That signals a powerful new lever for monetizing deeply engaged the company's fast-growing subscription business, advertising revenue growth trends after the glitch was addressed, and momentum in sponsored Snaps, management guided for continued top-line growth in Q3. Valuation remains a concern Despite a handful of promising trends at Snap, valuation remains troubling. The company has long leaned on equity dilution and stock-based compensation to fund growth. While Q2 did include a $243 million share repurchase (30 million shares), its stock-based compensation burden remains high. Full-year stock-based comp is still pegged north of $1.1 billion, even after recent downward revisions. Keep in mind that we're talking about a company with only a $12 billion market cap. Dilution continues to erode per-share value, even as Snap shows cash generation. So while the sell-off may feel overdone, the stock hasn't quite yet fallen low enough to make it a bargain. Of course, I could be wrong. A potential bull case lies not in near-term profits but in optionality -- whether Snap can scale newer revenue streams, stabilize pricing, and get to a point where it doesn't need to regularly materially dilute shareholders. Overall, Snap trades at a valuation that remains questionable given its history of dilution and heavy reliance on noncash compensation. But the emergence of fast-growing subscription revenue, sponsored Snaps, better cash flow, and an engaged user base make it extremely interesting -- worthy of a high spot on any investor's watchlist. Should you buy stock in Snap right now? Before you buy stock in Snap, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Snap wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Daniel Sparks and his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Snap Stock Plunged After Earnings. Buy the Dip? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
25 minutes ago
- Yahoo
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool Sign in to access your portfolio